Novel peptide derivatives from adiponectin and use thereof

A novel peptide derivative with enhanced properties addresses the solubility issues of adiponectin peptides, offering effective treatments for skin and hair issues, metabolic diseases, and cancer by increasing adiponectin expression and promoting hair growth, with improved stability and reduced side effects.

KR103043370B1Active Publication Date: 2026-11-06SEOUL NAT UNIV HOSPITAL +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020220165949
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-12-01
Publication Date
2026-11-06
Estimated Expiration
2042-12-01

AI Technical Summary

Technical Problem

Existing adiponectin-derived peptides face challenges with poor solubility and stability, limiting their efficacy in addressing skin aging, hair loss, metabolic diseases, and other health issues, and current treatments for these conditions have limited effectiveness and side effects.

Method used

Development of a novel peptide derivative with improved physical properties and activity, represented by Chemical Formula 1, which enhances adiponectin expression and promotes hair growth while inhibiting triglycerides, formulated for use in pharmaceutical and cosmetic compositions.

Benefits of technology

The peptide derivative exhibits higher stability and superior p-AMPK activity, effectively preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, as well as improving skin aging, sensitive skin, wrinkles, and moisturization with reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112022129353775-PAT00180_ABST
    Figure 112022129353775-PAT00180_ABST
Patent Text Reader

Abstract

The present invention relates to novel peptide derivatives, etc., wherein the peptide derivative is a partially modified adiponectin receptor peptide, and has the advantage of being advantageous for drug formulation due to its improved physical properties and activity, having higher stability and superior p-AMPK activity than the existing adiponectin receptor peptide. Accordingly, the peptide derivative of the present invention can be utilized for the prevention or treatment of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, as well as for the prevention or improvement of aging, sensitive skin, wrinkles, or moisturization.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to novel adiponectin-derived peptide derivatives and their uses, etc. Background Technology

[0003] Skin aging is caused by external and internal processes commonly associated with increased skin wrinkles, sagging, and drooping; external aging is generally referred to as 'photoaging' because it is primarily caused by repeated exposure to ultraviolet rays (UV). Naturally aged skin is smooth, pale, and has fine lines, whereas photoaged skin develops deep wrinkles and causes pigmentation and telangiectasia.

[0004] Subcutaneous fat plays an important role in maintaining energy homeostasis by secreting adipokines and hormones that regulate the metabolism of other tissues. Recently, it has been known that ultraviolet rays, an environmental factor that causes various diseases such as photoaging, inflammation, immunosuppression, and cancer, reduce the fat content of human subcutaneous fat tissue, decrease adiponectin—a fat-derived product—in aged skin, and induce an increase in MMP-1 and a decrease in collagen.

[0006] The human body has over 1.3 million hairs, with scalp hair comprising 100,000 to 150,000. Each hair has a distinct cycle, growing, maintaining, and shedding through a three-stage process consisting of the active growth phase (anagen), the apoptotic regression phase (catagen), and the resting phase (telogen). This cycle repeats over a period of 3 to 6 years, resulting in the normal shedding of an average of 50 to 100 hairs per day. Generally, "hair loss" refers to a condition in which hair is less than normal or absent due to various causes.

[0007] Today, the causes of hair loss include internal factors such as the action of male hormones and external factors such as mental stress in daily life and the accumulation of lipid peroxides on the scalp; it is known that these factors interact in a complex manner to manifest hair loss symptoms. Recently, in addition to male pattern baldness, the female population experiencing hair loss is also on the rise due to increased stress caused by changes in diet and the social environment. Furthermore, the number of people suffering from abnormal symptoms of the scalp and hair as described above is steadily increasing, and the age of those affected is also decreasing.

[0008] Currently available hair growth products suffer from a lack of distinct efficacy and side effects; they require continuous use and cause problems such as decreased sexual function, allergies, and depression.

[0010] Metabolic disease refers to a syndrome in which risk factors such as obesity, diabetes, hypertension, arteriosclerosis, and nonalcoholic fatty liver disease (NAFLD) occur together due to the accumulation of excess nutrients in the body and lack of exercise. Recently, it has been officially named metabolic syndrome or insulin resistance syndrome through the Adult Treatment Program III established by the World Health Organization and the National Institute of Health’s Heart, Lung, and Blood Institute. In addition, according to the ATP of the U.S. NCEP (National Cholesterol Education Program) published in 2001, if a patient exhibits three or more of the five risk factors—abdominal obesity with a waist circumference of 40 inches (102 cm) or more for men and 35 inches (88 cm) or more for women, triglycerides of 150 mg / dL or more, HDL cholesterol of 40 mg / dL or less for men and 50 mg / dL or less for women, blood pressure of 130 / 85 mmHg or more, and fasting glucose of 110 mg / dL or more—it is classified as a metabolic disease. In the case of Asians, the definition of abdominal obesity is adjusted somewhat to a waist circumference of 90 or more for men and 80 or more for women. There is also a recent research report stating that if these regulations are applied, about 25% of the entire Korean population exhibits symptoms of metabolic syndrome.

[0012] Meanwhile, adiponectin is a type of adipokine, a protein hormone specifically secreted by fat cells, and is known to play an important role in controlling cardiovascular diseases such as hyperglycemia, hyperinsulinism, obesity, and arteriosclerosis by enhancing insulin function and suppressing insulin resistance to block inflammation and prevent fat from accumulating in blood vessels. In addition, adiponectin has the function of inhibiting cancer cell metastasis and inflammatory responses, and can perform functions such as wound healing, inhibition of fibrosis, improvement of skin wrinkles, and moisturization by promoting the proliferation of keratinocytes as well as the expression of filaggrin, hyaluronic acid, and extracellular matrix in the skin.

[0013] Adiponectin is composed of 244 amino acids and consists of a signal sequence, a collagen-like domain located at the N-terminal, and a C1q-like globular domain located at the C-terminal. The hexamer and the 400 kDa homogeneous complex (HMW complex) are the major oligomers, and the homogeneous complex is known to be more active than the homogeneous complex (LMW complex).

[0014] The development of peptides modified from adiponectin, which are known to possess various biological activities, has been a target of many researchers and pharmaceutical companies both domestically and internationally, but the likelihood of final success has been relatively low due to the difficulty of forming polymers in the body.

[0016] Against this background, the inventors developed a short peptide derivative that can be applied to the skin by improving the physical properties and activity of existing adiponectin-derived peptides that are difficult to formulate due to their poor solubility, and completed the present invention by confirming the effects of increasing adiponectin expression, promoting hair growth, and inhibiting triglycerides. The problem to be solved

[0018] The object of the present invention is to provide a novel peptide derivative.

[0019] Another objective of the present invention is to provide a composition for increasing the expression of adiponectin comprising the above-mentioned peptide derivative as an active ingredient.

[0020] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0021] Another objective of the present invention is to provide a cosmetic composition for preventing or improving skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0022] Another objective of the present invention is to provide a pharmaceutical composition for preventing or improving aging, sensitive skin, wrinkles, or moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0023] Another objective of the present invention is to provide a cosmetic composition for preventing or improving aging, sensitive skin, wrinkles, or moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0024] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below. means of solving the problem

[0026] To solve the above problem, the present invention provides a peptide derivative represented by the following [Chemical Formula 1].

[0027] [Chemical Formula 1]

[0028]

[0029] In the above [Chemical Formula 1],

[0030] R1 is an amino group (NH2), an acetylamino group (Ac-NH), NH2-(CH2CH2O) m -CH2CONH, C 15 -C 20 One or more selected from the group consisting of an amide group and combinations thereof, wherein m may be an integer from 1 to 5, preferably 3, and the amide group is preferably C 16 It can be an amide group, namely a palmitamide group, and

[0031] R2 is an amino group or a hydroxyl group (OH), and

[0032] R3 is hydrogen (H), and

[0033] R4 is one or more selected from the group consisting of C1-C6 chain alkyl groups, C2-C6 alkylcarboxyl groups, C1-C6 alkylamide groups, imidazoylmethyl groups, and combinations thereof, and

[0034] R5 and R6 are identical or different from each other and are each independently a benzyl group, a phenylethyl group, or an indolylmethyl group, wherein the benzyl group is unsubstituted or is one or more selected from the group consisting of a hydroxyl group, a trifluoromethyl group (CF3), a halogen group, a cyano group, a nitro group, a C1-C6 chain alkyl group, a C1-C6 alkoxy group, and combinations thereof.

[0035] R7 is a benzyl group or a C1-C6 alkylamino group, wherein the benzyl group is unsubstituted or is one or more selected from the group consisting of a hydroxyl group, a halogen group, a cyano group, a nitro group, a C1-C6 chain-type alkyl group, a C1-C6 alkoxy group, and combinations thereof,

[0036] R3 and R7 are connected to each other, so C 15 -C 20 It forms a heterocycloalkene group, and

[0037] R8, R9, and R10 They are identical or different from each other, and each is independently hydrogen or a C1-C6 alkyl group, and

[0038] n can be 0 or 1, and

[0039] When n is 0, R4 is a C2-C6 alkylcarboxyl group, and R5, R6, and R7 may be benzyl groups, and

[0040] However, R1 is NH2, R2 is OH, R3 is hydrogen, R4 is an isobutyl group, R5 and R6 are both hydroxybenzyl groups, R7 is an unsubstituted benzyl group, and R8, R9, and R 10 All are hydrogen, and cases where n is 1 are excluded. That is, NH2-GLYYF-OH, known as the APN5 peptide, is excluded.

[0041] As one embodiment of the present invention, the R4 is , , , , , , It may be one or more selected from the group consisting of , and combinations thereof, but is not limited thereto.

[0042] In another embodiment of the present invention, R5 and R6 are identical or different from each other and are each independently , , , , , , , , , , , It may be one or more selected from the group consisting of , and combinations thereof, but is not limited thereto.

[0043] As another embodiment of the present invention, the above C 15 -C 20 The heterocycloalkene group , , , It may be one or more selected from the group consisting of , and combinations thereof, but is not limited thereto.

[0044] In another embodiment of the present invention, the peptide derivative may be one or more selected from the group consisting of peptide derivatives represented by [Chemical Formula 1-1] to [Chemical Formula 1-56] below, but is not limited thereto (Table 1).

[0045] Compound number Chemical formula number chemical formula DS-1 1-1 DS-2 1-2 DS-3 1-3 DS-4 1-4 DS-5 1-5 DS-6 1-6 DS-7 1-7 DS-8 1-8 DS-9 1-9 DS-10 1-10 DS-11 1-11 DS-12 1-12 DS-17 1-13 DS-18 1-14 DS-19 1-15 DS-20 1-16 DS-27 1-17 DS-28 1-18 DS-29 1-19 DS-30 1-20 DS-35 1-21 DS-36 1-22 DS-37 1-23 DS-38 1-24 DS-39 1-25 DS-40 1-26 DS-41 1-27 DS-42 1-28 DS-44 1-29 DS-45 1-30 DS-48 1-31 DS-49 1-32 DS-50 1-33 DS-51 1-34 DS-52 1-35 DS-53 1-36 DS-54 1-37 DS-55 1-38 DS-56 1-39 DS-57 1-40 DS-58 1-41 DS-59 1-42 DS-60 1-43 DS-61 1-44 DS-62 1-45 DS-63 1-46 DS-68 1-47 DS-70 1-48 DS-72 1-49 DS-73 1-50 DS-74 1-51 DS-75 1-52 DS-76 1-53 DS-77 1-54 DS-78 1-55 DS-79 1-56

[0047] In another embodiment of the present invention, the peptide derivative may be a modified version of one or more peptide sequences selected from the group consisting of SEQ ID NOs 1 to 16, but is not limited thereto (Table 2).

[0048] Sequence number Peptide sequence Compound number Chemical formula number 1 DYYF DS-27 1-17 DS-28 1-18 DS-29 1-19 DS-30 1-20 2 GDFYF DS-58 1-41 3 GDYFF DS-70 1-48 4 GDYYF DS-5 1-5 DS-6 1-6 DS-7 1-7 DS-8 1-8 DS-40 1-26 DS-41 1-27 DS-68 1-47 DS-78 1-55 DS-79 1-56 5 GDYYK DS-35 1-21 DS-36 1-22 6 GDYYY DS-76 1-53 DS-77 1-54 7 GEYYK DS-37 1-23 DS-38 1-24 8 GHYYF DS-44 1-29 DS-45 1-30 9 GIFYF DS-20 1-16 10 GIWYF DS-18 1-14 11 GIYYF DS-1 1-1 DS-2 1-2 DS-3 1-3 DS-4 1-4 12 GLFYF DS-19 1-15 DS-50 1-33 DS-51 1-34 DS-52 1-35 DS-53 1-36 DS-54 1-37 DS-57 1-40 13 GLWYF DS-17 1-13 14 GLYFF DS-59 1-42 DS-60 1-43 DS-61 1-44 DS-62 1-45 DS-63 1-46 15 GLYYF DS-39 1-25 DS-42 1-28 DS-48 1-31 DS-49 1-32 DS-55 1-38 DS-56 1-39 16 GNYYF DS-9 1-9 DS-10 1-10 DS-11 1-11 DS-12 1-12

[0050] In addition, the present invention provides a composition for increasing the expression of adiponectin comprising the above-mentioned peptide derivative as an active ingredient.

[0052] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0053] In addition, the present invention provides a method for preventing or treating one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the step of administering the peptide derivative to an individual.

[0054] In addition, the present invention provides the use of the peptide derivative for the manufacture of one or more preventive or therapeutic agents selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer.

[0055] In addition, the present invention provides a cosmetic composition for the prevention or improvement of one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0056] In addition, the present invention provides a food composition for the prevention or improvement of one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0058] In addition, the present invention provides a pharmaceutical composition for the prevention or improvement of one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0059] In addition, the present invention provides a method for preventing or improving one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the step of administering the peptide derivative to an individual.

[0060] In addition, the present invention provides the use of the peptide derivative for the manufacture of one or more drugs for the prevention or improvement of aging, sensitive skin, wrinkles, and moisturization selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization.

[0061] In addition, the present invention provides a cosmetic composition for the prevention or improvement of one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0062] In addition, the present invention provides a food composition for the prevention or improvement of one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the above-mentioned peptide derivative as an active ingredient. Effects of the invention

[0064] A peptide derivative according to one embodiment of the present invention is a modified adiponectin receptor peptide, having higher stability and superior p-AMPK activity than the existing adiponectin receptor peptide, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity.

[0065] Accordingly, the peptide derivative of the present invention can be utilized for the prevention or treatment of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, as well as for the prevention or improvement of aging, sensitive skin, wrinkles, or moisturization.

[0066] The effects of the peptide derivative according to one embodiment of the present invention are not limited to those mentioned above, and other unmentioned effects will be clearly understood by a person skilled in the art from the description below. Brief explanation of the drawing

[0068] FIG. 1 is a graph showing the effect of the peptide derivatives (DS-1 to DS-10) of the present invention, represented by [Chemical Formula 1-1] to [Chemical Formula 1-10], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. Figure 2 is a graph showing the effect of the peptide derivatives (DS-11, DS-12) of the present invention, represented by [Chemical Formula 1-11] and [Chemical Formula 1-12], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 3 is a graph showing the effect of the peptide derivatives (DS-17 to DS-20) of the present invention, represented by [Chemical Formula 1-13] to [Chemical Formula 1-16], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 4 is a graph showing the effect of the peptide derivatives (DS-27 to DS-30) of the present invention, represented by [Chemical Formula 1-17] to [Chemical Formula 1-20], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 5 is a graph showing the effect of the peptide derivatives (DS-35 to DS-38) of the present invention, represented by [Chemical Formula 1-21] to [Chemical Formula 1-24], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 6 is a graph showing the effect of the peptide derivatives of the present invention (DS-39 to DS-42, DS-44, DS-45) represented by [Chemical Formula 1-25] to [Chemical Formula 1-30] on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 7 is a graph showing the effect of the peptide derivatives (DS-48 to DS-56) of the present invention, represented by [Chemical Formula 1-31] ​​to [Chemical Formula 1-39], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 8 is a graph showing the effect of the peptide derivatives (DS-57 to DS-63) of the present invention, represented by [Chemical Formula 1-40] to [Chemical Formula 1-46], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 9 is a graph showing the effect of the peptide derivatives of the present invention (DS-68, DS-70, DS-72 to DS-75) represented by [Chemical Formula 1-47] to [Chemical Formula 1-52] on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 10 is a graph showing the effect of the peptide derivatives (DS-76 to DS-79) of the present invention, represented by [Chemical Formula 1-53] to [Chemical Formula 1-56], on AMPK phosphorylation activity in mouse adipocytes. In this case, V is the vehicle treated with DMSO, and P5 is the positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. FIG. 11 shows whether the AMPK phosphorylation activity, which was increased by the peptide derivatives of the present invention (DS-4, DS-5, DS-6, DS-8, DS-28, DS-43, DS-52) represented by [Formula 1-4], [Formula 1-5], [Formula 1-6], [Formula 1-8], [Formula 1-9], [Formula 1-18], and [Formula 1-35], decreases upon adiponectin receptor 1 knockdown. Here, NC is scrambled siRNA and R1 is adiponectin receptor 1 siRNA. V is a vehicle treated with DMSO, and P5 is a positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. DS-43 is an adiporon that acts as an agonist for adiponectin receptor 1. FIG. 12 shows whether the AMPK phosphorylation activity, which was increased by the peptide derivatives of the present invention (DS-2, DS-7, DS-17, DS-18, DS-27, DS-29, DS-48, DS-51) represented by [Formula 1-2], [Formula 1-7], [Formula 1-13], [Formula 1-14], [Formula 1-17], [Formula 1-19], [Formula 1-31], and [Formula 1-34], decreases upon adiponectin receptor 1 knockdown. Here, NC is scrambled siRNA and R1 is adiponectin receptor 1 siRNA. V is a vehicle treated with DMSO, and P5 is a positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. DS-43 is an adiporon that acts as an agonist for adiponectin receptor 1. Figure 13 confirms the cytotoxicity of the peptide derivative of the present invention represented by [Formula 1-6] on four cell lines (3T3-L1 adipocytes, RD muscle cells, keratinocytes, fibroblasts). In this case, Veh is a vehicle treated with DMSO. Figure 14 confirms the cytotoxicity of the peptide derivative of the present invention represented by [Formula 1-8] on four cell lines (3T3-L1 adipocytes, RD muscle cells, keratinocytes, fibroblasts). In this case, Veh is a vehicle treated with DMSO. Figure 15 confirms the cytotoxicity of the peptide derivative of the present invention represented by [Formula 1-18] on four cell lines (3T3-L1 adipocytes, RD muscle cells, keratinocytes, fibroblasts). In this case, Veh is a vehicle treated with DMSO. Figure 16 confirms the cytotoxicity of the peptide derivative of the present invention represented by [Formula 1-31] ​​on four cell lines (3T3-L1 adipocytes, RD muscle cells, keratinocytes, fibroblasts). In this case, Veh is a vehicle treated with DMSO. Figure 17 shows whether the peptide derivatives of the present invention represented by [Formula 1-6], [Formula 1-18], and [Formula 1-31] ​​increase AMPK phosphorylation activity in a concentration-dependent manner. Figure 18 shows the hair growth efficacy of the peptide derivatives of the present invention represented by [Chemical Formula 1-8], [Chemical Formula 1-18], and [Chemical Formula 1-31]. Here, V is a vehicle with EtOH : polyethylene glycol = 30 : 70, v / v, P5 is a positive control APN5 peptide having the sequence NH2-GLYYF-OH, and Mnx is a positive control minoxidil known as a hair growth agent. Figure 19 shows the skin aging improvement efficacy of the peptide derivatives of the present invention represented by [Chemical Formula 1-8], [Chemical Formula 1-18], and [Chemical Formula 1-31]. In this case, Veh is a vehicle treated with DMSO, and P5 is a positive control, which is the APN5 peptide. FIG. 20a shows the triglyceride removal efficacy of the peptide derivatives of the present invention represented by [Chemical Formula 1-8], [Chemical Formula 1-5], [Chemical Formula 1-6], [Chemical Formula 1-18], [Chemical Formula 1-2], [Chemical Formula 1-7], [Chemical Formula 1-31], and [Chemical Formula 1-50]. FIG. 20b shows the differentiation and triglyceride inhibition efficacy of the peptide derivatives of the present invention represented by [Chemical Formula 1-6], [Chemical Formula 1-8], [Chemical Formula 1-18], and [Chemical Formula 1-31]. In this case, V is a vehicle treated with DMSO, and P5 is a positive control, which is the APN5 peptide and has the sequence NH2-GLYYF-OH. ND is cultured in a non-differentiation medium and D is cultured in a differentiation medium. Figure 21 shows the efficacy of the peptide derivatives of the present invention for improving sensitive skin, represented by [Chemical Formula 1-8], [Chemical Formula 1-18], and [Chemical Formula 1-31]. In this case, Veh is a vehicle treated with DMSO, LA is lactic acid, and P5 is an APN5 peptide as a positive control. Specific details for implementing the invention

[0069] The present invention relates to the synthesis of a novel peptide derivative based on the adiponectin-derived peptide APN5, and more specifically, to a peptide in which some amino acids are modified to improve the physical properties and activity of the existing adiponectin peptide. The peptide derivative of the present invention is advantageous for drug formulation as it has improved efficacy, such as physical properties and activity.

[0071] Accordingly, the present invention provides a peptide derivative represented by the following [Chemical Formula 1].

[0072] [Chemical Formula 1]

[0073]

[0074] In the above [Chemical Formula 1],

[0075] R1 is an amino group (NH2), an acetylamino group (Ac-NH), NH2-(CH2CH2O) m -CH2CONH, C 15 -C 20 One or more selected from the group consisting of an amide group and combinations thereof, wherein m may be an integer from 1 to 5, and

[0076] R2 is an amino group or a hydroxyl group (OH), and

[0077] R3 is hydrogen (H), and

[0078] R4 is one or more selected from the group consisting of C1-C6 chain alkyl groups, C2-C6 alkylcarboxyl groups, C1-C6 alkylamide groups, imidazoylmethyl groups, and combinations thereof, and

[0079] R5 and R6 are identical or different from each other and are each independently a benzyl group, a phenylethyl group, or an indolylmethyl group, wherein the benzyl group is unsubstituted or is one or more selected from the group consisting of a hydroxyl group, a trifluoromethyl group (CF3), a halogen group, a cyano group, a nitro group, a C1-C6 chain alkyl group, a C1-C6 alkoxy group, and combinations thereof.

[0080] R7 is a benzyl group or a C1-C6 alkylamino group, wherein the benzyl group is unsubstituted or is one or more selected from the group consisting of a hydroxyl group, a halogen group, a cyano group, a nitro group, a C1-C6 chain-type alkyl group, a C1-C6 alkoxy group, and combinations thereof,

[0081] R3 and R7 are connected to each other, so C 15 -C 20 It forms a heterocycloalkene group, and

[0082] R8, R9, and R 10They are identical or different from each other, and each is independently hydrogen or a C1-C6 alkyl group, and

[0083] n can be 0 or 1.

[0085] In the present invention, the term “substitution” refers to a reaction that replaces an atom or atomic group contained in a molecule of a compound with another atom or atomic group.

[0086] In the present invention, the term “chain-type” refers to a molecule having a chain-type structure. A chain-type structure is a chemical structure in which carbon atoms are connected in a chain shape, and includes straight chain-type and branched chain-type structures.

[0087] In the present invention, the term “cyclic” refers to a structure in which the two ends of a chain formed in the backbone of an organic compound are joined to form a ring shape.

[0088] In the present invention, the term “chain or cyclic alkyl group” means a monovalent linear, branched, or cyclic saturated hydrocarbon residue having 1 to 12 carbon atoms and composed only of carbon and hydrogen atoms. Examples of such alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, 2-butyl, 3-butyl, pentyl, n-hexyl, cyclobutyl group, cyclopentyl group, cyclohexyl group, etc.

[0089] In the present invention, the term “halogen group” refers to elements belonging to Group 17 of the periodic table, such as fluorine (F), chloride (Cl), bromine (Br), or iodine (I).

[0090] In the present invention, the term “alkoxy group” means an atomic group CnH2n+1O- formed by the bonding of an oxygen atom to an alkyl group, and examples of such alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, or ptoxy.

[0091] In the present invention, the term “cycloalkene group” is also referred to as a cyclic alkene group and refers to a ring group in which all ring members are carbon and have one or more double bonds (but are not aromatic). The term “heterocycloalkene group” refers to a cycloalkene group comprising at least one heteroatom of N, O, or S. Each of the cycloalkene group or heterocycloalkene group comprises one or more ring structures, which may be, for example, a single ring, a double ring, a triple ring, etc.

[0093] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0094] In addition, the present invention provides a pharmaceutical composition for the prevention or improvement of one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0095] In the present invention, the term "prevention" refers to any act of suppressing or delaying the occurrence, spread, or recurrence of the said disease by administering the composition of the present invention, and the term "treatment" refers to any act of improving or beneficially altering the symptoms of the said disease by administering the composition of the present invention.

[0096] In the present invention, the term "improvement" refers to any action that beneficially changes parameters related to the condition being treated, such as at least reducing the severity of symptoms or improving the disease.

[0097] In the present invention, the term "pharmaceutical composition" means that it is prepared for the purpose of preventing or treating the above disease, and can be formulated into various forms according to conventional methods. For example, it can be formulated into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and can be formulated into external preparations, suppositories, and sterile injectable solutions.

[0098] In the present invention, "included as an active ingredient" means that the corresponding ingredient is included in an amount necessary or sufficient to realize the desired biological effect. In actual application, the amount included as an active ingredient is determined as an amount for treating the target disease, taking into account factors that do not cause other toxicities, and may vary depending on various factors such as, for example, the disease or condition being treated, the form of the composition administered, the size of the subject, or the severity of the disease or condition. A person skilled in the art to which the present invention pertains can empirically determine the effective amount of an individual composition without involving excessive experimentation.

[0099] In addition, the pharmaceutical composition of the present invention may include one or more pharmaceutically acceptable carriers in addition to the active ingredients described above, depending on each formulation.

[0100] The above-mentioned pharmaceutically acceptable carrier may be saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components, and may further include other conventional additives such as antioxidants, buffers, and bacteriostatic agents as needed. Additionally, by additionally adding diluents, dispersants, surfactants, binders, and lubricants, it may be formulated into injectable formulations such as aqueous solutions, suspensions, and emulsions, or into pills, capsules, granules, or tablets. Furthermore, it may be preferably formulated according to each disease or component by appropriate methods in the art or by using methods disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton, PA).

[0101] The composition of the present invention may be administered orally or parenterally in a pharmaceutically effective amount according to the intended method, and the term “pharmaceutically effective amount” of the present invention means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level may be determined based on factors including the patient’s health status, severity, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field.

[0102] In the present invention, “skin inflammatory disease” refers to inflammation occurring in the outer layer of the skin that causes itching, blisters, redness, swelling, and often exudation, scabbing, and peeling. Non-limiting examples include, but are not limited to, psoriasis, atopic dermatitis, eczema, contact dermatitis, erythroderma, chronic simple lichen, nummular dermatitis, seborrheic dermatitis, and stasisal dermatitis.

[0103] In the present invention, “metabolic disease” refers to a syndrome in which risk factors such as obesity, diabetes, hypertension, arteriosclerosis, and nonalcoholic fatty liver disease (NAFLD) appear together due to the accumulation of excess nutrients in the body and lack of exercise, and non-limiting examples include diabetes, hypertension, hyperlipidemia, cardiovascular and cerebrovascular diseases, thrombosis, dyslipidemia, stroke, arteriosclerosis, and hyperinsulinemia, but are not limited thereto.

[0105] In addition, the present invention provides a method for preventing or treating one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the step of administering the peptide derivative to an individual.

[0106] In addition, the present invention provides a method for preventing or improving one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the step of administering the peptide derivative to an individual.

[0107] In the present invention, the term “individual” is not limited to mammals such as livestock or humans that require prevention, treatment, and / or diagnosis of the disease, but preferably may be a human.

[0108] The term "administration" in the present invention means providing a specific substance to a patient by any appropriate method. The pharmaceutical composition of the present invention may be formulated into various forms for administration to an individual, and representative formulations for parenteral administration are injectable formulations, preferably isotonic aqueous solutions or suspensions. Injectable formulations may be prepared according to techniques known in the art using suitable dispersants or wetting agents and suspending agents. For example, each component may be dissolved in saline solution or a buffer solution to be formulated for injection. Additionally, formulations for oral administration include, for example, ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers, and these formulations may contain, in addition to the active ingredient, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and a lubricant (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol). The above tablet may include a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and optionally may further include a disintegrant such as starch, agar, alginic acid or its sodium salt, an absorbent, a coloring agent, a flavoring agent and / or a sweetener. The above formulation may be prepared by conventional mixing, granulation, or coating methods.

[0109] In addition, the pharmaceutical composition of the present invention may further include adjuvants such as preservatives, hydrating agents, emulsification promoters, salts or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated according to conventional methods.

[0110] The pharmaceutical composition according to the present invention may be administered via various routes including oral, transdermal, subcutaneous, intravenous, nasal, intraperitoneal, or intramuscular, and the dosage of the active ingredient may be appropriately selected according to various factors such as the route of administration, the patient's age, gender, body weight, and severity of the patient. In addition, the composition of the present invention may be administered in combination with known compounds that can enhance the desired effect.

[0112] In addition, the present invention provides a cosmetic composition for the prevention or improvement of one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0113] In addition, the present invention provides a cosmetic composition for the prevention or improvement of one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0114] The above cosmetic composition may be prepared in the form of, for example, a basic cosmetic composition (such as a lotion, cream, essence, facial cleanser such as cleansing foam and cleansing water, pack, body oil), color cosmetic composition (foundation, lipstick, mascara, makeup base), hair product composition (shampoo, rinse, hair conditioner, hair gel), and soap, together with dermatologically acceptable excipients, and may include the above peptide derivative or a cosmetically acceptable salt thereof as an active ingredient.

[0115] The above excipients may include, for example, skin softeners, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners, and solvents, and more specifically, starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, anhydrous skim milk, glycerol, propylene, glycol, water, ethanol, etc., but are not limited thereto.

[0117] In addition, the present invention provides a food composition for the prevention or improvement of one or more conditions selected from the group consisting of skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, and cancer, comprising the above-mentioned peptide derivative as an active ingredient.

[0118] In addition, the present invention provides a food composition for the prevention or improvement of one or more selected from the group consisting of aging, sensitive skin, wrinkles, and moisturization, comprising the above-mentioned peptide derivative as an active ingredient.

[0119] The above food composition comprises, for example, the above peptide derivative or a pharmaceutically acceptable salt thereof as an active ingredient. When the above peptide derivative is used as an additive to the food composition, it may be added as is or used together with other foods or food ingredients, or it may be used appropriately according to conventional methods. Generally, when manufacturing food or beverages, the composition of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, relative to the raw materials. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there are no issues regarding safety, the active ingredient may be used in an amount greater than the above range. That is, the amount of the active ingredient can be appropriately determined according to each purpose of use, such as prevention, health, or treatment.

[0120] The formulation of the above food composition can be in the form of powder, granule, pill, tablet, or capsule, as well as any form of general food or beverage.

[0121] The food of the present invention can be manufactured by methods commonly used in the industry, and can be manufactured by adding raw materials and ingredients commonly added in the industry. Specifically, it may include protein, carbohydrates, fats, nutrients, seasonings, and flavorings, and examples of the carbohydrates include glucose, fructose, maltose, sucrose, oligosaccharides, dextrin, cyclodextrin, xylitol, sorbitol, erythrol, saccharin, or synthetic flavorings, but are not limited thereto.

[0123] The terms used in the embodiments are for illustrative purposes only and should not be interpreted as intended to be limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0124] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0125] In describing the components of the embodiments, terms such as first, second, A, B, (a), (b), etc., may be used. These terms are intended merely to distinguish the components from other components, and the nature, order, or sequence of the components is not limited by these terms. Where it is stated that a component is "connected," "combined," or "joined" to another component, it should be understood that the component may be directly connected or joined to the other component, but that another component may also be "connected," "combined," or "joined" between each component.

[0127] Hereinafter, embodiments are described in detail with reference to the attached drawings. However, various modifications may be made to the embodiments, and thus the scope of the patent application is not limited or restricted by these embodiments. It should be understood that all modifications, equivalents, and substitutions to the embodiments are included within the scope of the rights.

[0128] In addition, when describing with reference to the attached drawings, identical components are assigned the same reference numeral regardless of drawing symbols, and redundant descriptions thereof are omitted. When describing embodiments, if it is determined that a detailed description of related prior art could unnecessarily obscure the essence of the embodiment, such detailed description is omitted.

[0130] The present invention is capable of various modifications and may have various embodiments. Specific embodiments are illustrated in the drawings and described in detail in the detailed description below. However, this is not intended to limit the present invention to specific embodiments, and it should be understood that it includes all modifications, equivalents, and substitutions that fall within the spirit and scope of the present invention. In describing the present invention, detailed descriptions of related prior art are omitted if it is determined that such detailed descriptions may obscure the essence of the present invention.

[0132] Example 1. Preparation of the peptide derivative of the present invention

[0133] The peptide derivative of the present invention was prepared using a conventional amino acid synthesis method (Umbarger. HE, Ann. Rev. Biochem. 1978, 47, 533-606).

[0134] The C-terminal origin is Wang resin (100-200 mesh, Novabiochem ® Preparation of a peptide with a common C-terminus consisting of a COOH carboxyl group using Rink amide AM resin (100-200 mesh, Novabiochem , CAS No: 65307-53-1) and ® A peptide is prepared using (CAS No: 65307-53-1) in which the C-terminus is a CONH2 amide terminal.

[0136] Example 1.1. The case where the N-terminus is an amino group and the C-terminus is a carboxyl group

[0137] To prepare a peptide consisting of a C-terminal carboxyl group, dried Wang resin (100 mg, 0.5 - 1.3 mmol / g) was stirred in dichloromethane (DCM) solvent for 60 minutes using a Torviq polypropylene syringe reaction vessel, and then the solvent was removed to start the first step of the reaction. The first step of the reaction involved stirring hydroxybenzotriazole (1-Hydroxybenzotriazole, HOBt), diisopropylcarbodiimide (N,N'-Diisopropylcarbodiimide, DIC), 4-dimethylaminopyridine (4-Dimethylaminopyridine, DMAP) and the first amino acid residue Fmoc-Phe-OH for 2 hours in a solvent of dichloromethane (DCM) and dimethylformamide (DMF) in a 3:2 ratio, and then washing the resin by repeating the washing process twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). For the second step of peptide monomer synthesis, to remove the Fmoc protecting group, the reaction was carried out twice for 10 minutes each at room temperature using 1 mL of dimethylformamide (DMF) containing 20% ​​(v / v) piperidine; afterward, the resin was washed by repeating the above washing process twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF); and then hydroxybenzotriazole (HOBt), N-[(dimethylamino-)-1H-1,2,3-triazolo[4,5-b]pyridine-1-yl-methylene]-N-methylmethaneminium hexafluorophosphate N-oxide (HATU), N,N-diisopropylethylamine (DIEA) and Fmoc-Tyr(OtBu)-OH was stirred in dimethylformamide (DMF) solvent for 2 hours to complete the reaction.The reaction-completed resin was washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). The synthesis of peptide monomers in the subsequent steps was carried out through the same process as the second monomer synthesis step. The peptides from which the monomer synthesis was completed were finally subjected to a reaction to remove the Fmoc protecting group of the final peptide of the resin. This reaction was carried out twice for 10 minutes each at room temperature using 1 mL of dimethylformamide (DMF) with 20% (v / v) piperidine added, and then the washing process was completed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). The peptide was purified using high-performance liquid chromatography (Prep-HPLC, Gilson) with a gradient solvent composition of acetonitrile and water. For purity verification and analysis, RP-HPLC and LC-MS were used to obtain peptides with a purity of over 98%.

[0139] Example 1.2. Case where the N-terminus is an amino group and the C-terminus is an amide group

[0140] To prepare a peptide consisting of C-terminal amide groups, the first step of the reaction is initiated by stirring dried Rink amide AM resin (100 mg, 0.9 mmol / g) in dimethylformamide (DMF) solvent for 60 minutes using a Torviq polypropylene syringe reaction vessel, and then removing the solvent. To remove the Fmoc protecting group from the resin, the Fmoc-Rink amid MBHA resin was reacted twice for 10 minutes each at room temperature using 1 mL of dimethylformamide (DMF) containing 20% ​​(v / v) piperidine; afterward, the resin was washed by repeating the above washing process twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF); and then, for the introduction of the first amino acid residue, hydroxybenzotriazole (1-Hydroxybenzotriazole, HOBt), N-[(dimethylamino-)-1H-1,2,3-triazolo[4,5-b]pyridine-1-yl-methylene]-N-methylmethaneminium hexafluorophosphate N-oxide (HATU), N,N-diisopropylethylamine (DIEA) and Fmoc-Phe-OH were reacted and stirred in dimethylformamide (DMF) solvent for 2 hours. The resin after the reaction was completed was washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF).For the second step of peptide monomer synthesis, to remove the Fmoc protecting group, the reaction was carried out twice for 10 minutes each at room temperature using 1 mL of dimethylformamide (DMF) containing 20% ​​(v / v) piperidine; afterward, the resin was washed by repeating the above washing process twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF); and then hydroxybenzotriazole (HOBt), N-[(dimethylamino-)-1H-1,2,3-triazolo[4,5-b]pyridine-1-yl-methylene]-N-methylmethaneminium hexafluorophosphate N-oxide (HATU), N,N-diisopropylethylamine (DIEA) and Fmoc-Tyr(OtBu)-OH was reacted and stirred in dimethylformamide (DMF) solvent for 2 hours. The reacted resin was washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). The peptide monomer synthesis in the subsequent steps was carried out following the same process as the monomer synthesis step above. Finally, to remove the Fmoc protecting group from the last peptide of the resin, 1 mL of dimethylformamide (DMF) containing 20% ​​(v / v) piperidine was added, and the reaction was carried out twice for 10 minutes at room temperature. Afterward, the washing process was completed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). The peptide was purified using high-performance liquid chromatography (Prep-HPLC, Gilson) with a gradient solvent composition of acetonitrile and water. For purity verification and analysis, RP-HPLC and LC-MS were used to obtain peptides with a purity of over 98%.

[0142] Example 1.3. Acetylprotection of the N-terminus

[0143] Acetic anhydride and N,N-diisopropylethylamine (DIEA) were added to the unprotected N-terminus peptide synthesized in Example 1.1 or 1.2 and the mixture was stirred in dimethylformamide (DMF) solvent for 2 hours. The resulting resin was washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF) to synthesize a peptide with an acetyl group-protected N-terminus. The peptide was purified using high-performance liquid chromatography (Prep-HPLC, Gilson) with a gradient solvent composition of acetonitrile and water. Peptides with a purity of 98% or higher were obtained using RP-HPLC and LC-MS for purity verification and analysis.

[0145] Example 1.4. PAL protection of the N-terminus

[0146] To synthesize a PAL (Palmitic acid) protected peptide on the unprotected N-terminal peptide synthesized in Example 1.1 or 1.2, hydroxybenzotriazole (1-Hydroxybenzotriazole, HOBt), N-[(dimethylamino-)-1H-1,2,3-triazolo[4,5-b]pyridine-1-yl-methylene]-N-methylmethaneminium hexafluorophosphate N-oxide (HATU), N,N-diisopropylethylamine (N,N-diisopropylethylamine, DIEA), and PEG (2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)acetic acid) or PAL (Palmitic acid) were reacted and stirred in dimethylformamide (DMF) solvent for 2 hours. The reaction-completed resin was washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF).

[0147] The crude peptide obtained by the above method was reacted for 2 to 3 hours with a separation solution of trifluoroacetic acid (TFA):H2O:triisopropylsilane (TIPS) (95:2.5:2.5 vol. / vol.) to remove the protecting group and separate the peptide from the resin, and then the peptide was precipitated with cooled diethyl ether. The peptide was purified using high-performance liquid chromatography (Prep-HPLC, Gilson) with a gradient solvent composition of acetonitrile and water. For purity verification and analysis, RP-HPLC and LC-MS were used to obtain peptides with a purity of 98% or higher.

[0149] Example 1.5. PEG protection of the N-terminus

[0150] To synthesize a peptide protected with (PEG)3 (2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)acetic acid) on the unprotected N-terminal peptide synthesized in Example 1.1 or 1.2, hydroxybenzotriazole (1-Hydroxybenzotriazole, HOBt), N-[(dimethylamino-)-1H-1,2,3-triazolo[4,5-b]pyridine-1-yl-methylene]-N-methylmethaneminium hexafluorophosphate N-oxide (HATU), N,N-diisopropylethylamine (N,N-diisopropylethylamine, DIEA), and PEG (2-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)acetic acid) or PAL (Palmitic acid) were reacted and stirred in dimethylformamide (DMF) solvent for 2 hours. The reaction-completed resin was washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF).

[0151] The crude peptide obtained by the above method was reacted for 2 to 3 hours with a separation solution of trifluoroacetic acid (TFA):H2O:triisopropylsilane (TIPS) (95:2.5:2.5 vol. / vol.) to remove the protecting group and separate the peptide from the resin, and then the peptide was precipitated with cooled diethyl ether. The peptide was purified using high-performance liquid chromatography (Prep-HPLC, Gilson) with a gradient solvent composition of acetonitrile and water. For purity verification and analysis, RP-HPLC and LC-MS were used to obtain peptides with a purity of 98% or higher.

[0153] Example 1.6. Synthesis of Cyclic Peptide

[0154] A peptide was synthesized using the method of Example 1.2 for preparing a peptide consisting of a C-terminal amide group. After synthesizing a linear peptide using Fmoc-Allyl-Gly-OH for the first and last amino acids in the same manner as the synthesis method of Example 1.2, a resin with an N-terminus protected by Fmoc was reacted at 100°C for 1 to 2 hours using a microwave (2.5 GHz, 300 W) with LiCl (0.4 M) dissolved in dimethylformamide (DMF) and Grubbs' catalyst added under dichloromethane (DCM) solvent. The resin was then washed twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). Finally, as a reaction to remove the Fmoc protecting group from the last peptide of the resin, the reaction was carried out twice for 10 minutes each at room temperature using 1 mL of dimethylformamide (DMF) with 20% (v / v) piperidine added, and then the washing process was completed by repeating the above washing process twice each using dimethylformamide (DMF), methyl alcohol (MeOH), dichloromethane (DCM), and finally dimethylformamide (DMF). The crude peptide obtained by the above method was reacted for 2 to 3 hours with a separation solution of trifluoroacetic acid (TFA):H2O:triisopropylsilane (TIPS) (95:2.5:2.5 vol. / vol.) to remove the protecting group and separate the peptide from the resin, and then the peptide was obtained by precipitating it with cooled diethyl ether. The peptide was purified using high-performance liquid chromatography (Prep-HPLC, Gilson) with a gradient solvent composition of acetonitrile and water. For purity verification and analysis, peptides with a purity of over 98% were obtained using RP-HPLC and LC-MS (J. Pept. Sci. 2007; 13: 280-285).

[0156] The sequence and molecular weight of the peptide derivative according to one embodiment of the present invention are as shown in Table 3 below.

[0157] Compound number Chemical formula number order Measured molecular weight [M+H] + DS-1 1-1 NH2-GlYYF-OH 662.25 DS-2 1-2 AcNH-GlYYF-OH 661.25 DS-3 1-3 NH2-GlYYF-NH2 703.24 DS-4 1-4 AcNH-GlYYF-NH2 664.17 DS-5 1-5 NH2-GDYYF-OH 706.19 DS-6 1-6 AcNH-GDYYF-OH 663.20 DS-7 1-7 NH2-GDYYF-NH2 705.21 DS-8 1-8 AcNH-GDYYF-NH2 663.20 DS-9 1-9 NH2-GNYYF-OH 663.20 DS-10 1-10 AcNH-GNYYF-OH 705.20 DS-11 1-11 NH2-GNYYF-NH2 662.23 DS-12 1-12 Ac-NH-GNYYF-NH2 704.22 DS-17 1-13 NH2-GLWYF-NH2 684.27 DS-18 1-14 NH2-GIWYF-NH2 684.28 DS-19 1-15 NH2-GLFYF-NH2 645.27 DS-20 1-16 NH2-GIFYF-NH2 645.28 DS-27 1-17 NH2-DYYF-OH 607.13 DS-28 1-18 AcNH-DYYF-OH 649.18 DS-29 1-19 NH2-DYYF-NH2 606.20 DS-30 1-20 AcNH-DYYF-NH2 648.25 DS-35 1-21 NH2-GDYYK-NH2 644.18 DS-36 1-22 AcNH-GDYYK-NH2 686.24 DS-37 1-23 NH2-GEYYK-NH2 658.24 DS-38 1-24 AcNH-GEYYK-NH2 700.26 DS-39 1-25 NH2-GLYY(Dmt)F-NH2 689.26 DS-40 1-26 NH2-GDYY(Dmt)F-NH2 691.23 DS-41 1-27 NH2-GDY(Dmt)YF-NH2 691.25 DS-42 1-28 NH2-GLY(Dmt)YF-NH2 689.30 DS-44 1-29 NH2-GHYYF-NH2 685.23 DS-45 1-30 AcNH-GHYYF-NH2 727.26 DS-48 1-31 NH2-GLYYF(N-Me)-NH2 675.29 DS-49 1-32 NH2-GLYYF(homo)-NH2 675.28 DS-50 1-33 NH2-GLF(OMe)YF-NH2 675.28 DS-51 1-34 NH2-GLF(4-F)YF-NH2 663.26 DS-52 1-35 NH2-GLF(4-Cl)YF-NH2 679.23 DS-53 1-36 NH2-GLF(4-CN)YF-NH2 670.27 DS-54 1-37 NH2-GLF(4-NO2)YF-NH2 690.26 DS-55 1-38 NH2-GLYY(N-Me)F-NH2 675.26 DS-56 1-39 NH2-GLY(N-Me)YF-NH2 675.28 DS-57 1-40 NH2-GLF(4-Cl)YF(homo)-NH2 693.24 DS-58 1-41 NH2-GDF(4-Cl)YF-NH2 681.17 DS-59 1-42 NH2-GLYF(OMe)F-NH2 675.27 DS-60 1-43 NH2-GLYF(4-F)F-NH2 663.26 DS-61 1-44 NH2-GLYF(4-Cl)F-NH2 679.24 DS-62 1-45 NH2-GLYF(4-CN)F-NH2 670.26 DS-63 1-46 NH2-GLYF(4-NO2)F-NH2 690.25 DS-68 1-47 NH2-GDYYF(homo)-NH2 677.20 DS-70 1-48 NH2-GDYF(4-Cl)F-NH2 681.15 DS-72 1-49 Cyclic 623.22 DS-73 1-50 Cyclic 637.25 DS-74 1-51 Cyclic 637.24 DS-75 1-52 Cyclic 651.27 DS-76 1-53 AcNH-GDY(N-Me)YY-NH2 735.21 DS-77 1-54 AcNH-GDYYY(N-Me)-NH2 735.30 DS-78 1-55 PAL-NH-GDYYF-NH2 901.45 DS-79 1-56 NH2-(PEG)3-NH-GDYYF-NH2 852.28

[0159] In Table 3 above, each amino acid constituting the peptoid derivative of the present invention may have the following structure.

[0160]

[0162] 실험예 1. 생체 외( in vitro ) Verification of AMPK phosphorylation activity

[0163] The effects of the peptide derivatives of the present invention on the expression and receptor activity of adiponectin in mouse adipocytes, the major site of adiponectin production, were investigated. Mouse adipocyte cell line 3T3-L1 was treated with the peptide derivatives of the present invention at a concentration of 10 μM each and cultured for 24 hours, after which cells were obtained. Subsequently, proteins were extracted, and their effects on AMPK phosphorylation, which is responsible for major downstream signaling of adiponectin, were investigated using Western blot.

[0164] As a result, the peptide derivatives of the present invention increased AMPK phosphorylation activity associated with the activity of adiponectin receptors in mouse adipocytes (Figs. 1 to 10), and in particular, it was confirmed that the peptide derivatives represented by [Formula 1-2], [Formula 1-4] to [Formula 1-9], [Formula 1-13], [Formula 1-14], [Formula 1-17] to [Formula 1-19], [Formula 1-31], [Formula 1-34], and [Formula 1-35] had a significant increase in AMPK phosphorylation activity even compared to APN5, a conventionally known adiponectin-derived peptide (Table 4).

[0165] Compound number Chemical formula number AMPK phosphorylation activity (fold change) DS-8 1-8 2.6 DS-5 1-5 2.0 DS-6 1-6 1.9 DS-28 1-18 1.9 DS-4 1-4 1.8 DS-9 1-9 1.6 DS-48 1-31 1.5 DS-2 1-2 1.3 DS-7 1-7 1.3 DS-27 1-17 1.3 DS-51 1-34 1.3 DS-17 1-13 1.2 DS-18 1-14 1.2 DS-29 1-19 1.2 DS-52 1-35 1.2 DS-43 adiporon 1.2 APN5 P5 1.0

[0167] Experimental Example 2. In vitro ( in vitro Verification of loss of AMPK phosphorylation activity after adiponectin receptor 1 knockdown

[0168] To verify whether the peptide derivative of the present invention binds to adiponectin receptor 1, mouse adipocyte cell line 3T3-L1 was knocked down by treating it with siRNA of adiponectin receptor 1, and then treated with the peptide derivative of the present invention at a concentration of 10 μM each and cultured for 24 hours, after which the cells were obtained. Subsequently, proteins were extracted, and Western blot was used to confirm whether the AMPK phosphorylation activity, which had been increased by the peptide derivative, was lost.

[0169] As a result, it was confirmed that the peptide derivatives of the present invention, including [Formula 1-2], [Formula 1-5] to [Formula 1-8], [Formula 1-13], [Formula 1-14], [Formula 1-17] to [Formula 1-19], [Formula 1-31], [Formula 1-34], and [Formula 1-35], reduce AMPK phosphorylation activity after knockdown of adiponectin receptor 1 (Figs. 11 and 12).

[0170] Adiponectin acts by binding to adiponectin receptors, and it is known that activation of adiponectin receptors increases the phosphorylation of the downstream signaling pathway AMPK and the activity of PPARα / PPARγ (Crystal structures of the human adiponectin receptors. Nature. 2015 Apr16;520(7547):312-6. doi: 10.1038 / nature14301). In addition, it is known that the expression of adiponectin and its receptors is reduced in photoaged skin and UV-irradiated skin, and that such a decrease in adiponectin expression can alter the extracellular matrix and exacerbate photoaging by regulating the expression of skin aging regulators MMP-1 and procollagen (UV-induced inhibition of adipokine production in subcutaneous fat aggravates dermal matrix degradation in human skin.2016.Scientific Reports.10;6:25616. doi:10.1038 / srep25616).

[0171] Therefore, the peptide derivative of the present invention increases AMPK phosphorylation activity associated with the activity of adiponectin receptors, thereby increasing the expression of adiponectin in the body and suggesting that it can play a major role in defending against skin aging.

[0173] Experimental Example 3. In vitro ( in vitro ) Cytotoxicity Verification

[0174] Using four cell lines (3T3-L1 adipocytes, RD muscle cells, keratinocytes, and fibroblasts), 5 × 10⁶ cells of each type were placed in a 24-well plate per well. 4After dispensing into individual cells, they were cultured for 24 hours under each cell culture condition. The medium was discarded, washed with PBS, and replaced with fresh medium that does not contain 10% FBS. The peptide derivatives of the present invention were then treated at different concentrations (0, 0.1, 1, 10, 100, 500 μM) and cultured for 24 hours. The medium was carefully removed and washed with PBS. Then, the MTT reagent was added according to the manufacturer's instructions, reacted at room temperature for 30 minutes, and the absorbance was measured at 450 nm.

[0175] As a result, the peptide derivatives of the present invention, including [Formula 1-6], [Formula 1-8], [Formula 1-18], and [Formula 1-31], were confirmed to be non-toxic in a number of cell lines (Figs. 13 to 16).

[0177] Experimental Example 4. In vitro ( in vitro Verification of concentration dependence of AMPK phosphorylation activity

[0178] 3T3-L1 mouse adipocyte cell line was treated with the peptide derivative of the present invention at a series of concentrations (0, 0.01, 0.1, 1, 10, 100 μM) and cultured for 24 hours, after which cells were obtained. Subsequently, proteins were extracted, and the concentration-dependent effect of the peptide derivative on AMPK phosphorylation was confirmed by Western blot.

[0179] As a result, it was confirmed that the peptide derivatives of the present invention, including [Formula 1-6], [Formula 1-18], and [Formula 1-31], increase AMPK phosphorylation activity in a concentration-dependent manner (Fig. 17).

[0181] Experimental Example 5. Solubility Test

[0182] PRISMA HT solution was diluted with distilled water at a ratio of 1:40 and adjusted to pH 7.4 to be used as a test buffer. In addition, reference substances (Diclofenac stock 50 mM, Phenazopyridine stock 25 mM) used for accuracy in general solubility tests and the peptide derivative of the present invention (50 mM) as a test substance were prepared in DMSO and used as test standard solutions.

[0183] 10 mL of the prepared test substance was diluted in 190 μL of isopropyl alcohol. Additionally, 75 mL of the test solution and 70 mL of isopropyl alcohol were mixed to be used as a blank sample, and 5 mL of the test substance diluted in isopropyl alcohol was added to the blank sample. After mixing the diluted samples, the absorbance was measured and used as the initial test value. For the solubility test, 1 mL of the test solution was mixed with 10 mL of DMSO test standard solution and reacted at room temperature for 24 hours. Afterward, the precipitate was removed from the sample using a filter plate, and 75 mL of isopropyl alcohol was added to 74 mL of the filtered sample, and the absorbance was measured and used as the sample value.

[0184] The solubility values ​​of the test substances were analyzed using msol Explorer (Solubility Explorer program) after measuring the absorbance of each sample using a microplate reader. The mean and standard deviation of the values ​​from three repeated experiments (n = 3) were calculated using Excel.

[0185] As a result, the peptide derivative of the present invention exhibited excellent solubility in DMSO (Table 5).

[0186] Compound number Chemical formula number Average DMSO Solubility (μg / ml) DS-2 1-2 348.0 DS-5 1-5 328.0 DS-6 1-6 349.0 DS-8 1-8 349.0 DS-27 1-17 300.0 DS-28 1-18 321.0 DS-29 1-19 300.0 DS-43 adiporon 43.7 DS-48 1-31 334.0 DS-51 1-34 135.5 DS-73 1-50 315.0 APN5 P5 8.2 Diclofenac (reference) 157.0 Phenazopyridine(reference) 23.76

[0188] Experimental Example 6. Plasma stability test

[0189] The peptide derivative of the present invention was added to two types of plasma (Human, Rat) at a concentration of 1 μM and placed in respective tubes, which were then incubated at 37°C for a period of time (0, 30, 60, 120, 240 minutes). At each time interval, the tube containing the plasma was removed, an acetonitrile solution containing an internal standard (chlorpropamide) was added, the tube was vortexed for 5 minutes, and the tube was centrifuged for 5 minutes (14,000 rpm, 4°C). The supernatant was then injected into an LC-MS / MS system to analyze the drug at each time interval, thereby evaluating the plasma stability of the peptide derivative. At this time, Procaine and Enalapril were used as reference substances for accuracy in general plasma stability tests.

[0190] The amount of drug remaining in each tube after the above reaction was analyzed by LC-MS / MS using a Shimadzu Nexera XR system and TSQ vantage (Thermo). A Luna C18 column (2.0 × 50 mm, 3 μm particle size; Phenomenex, US) was used for the HPLC column, and the mobile phase consisted of distilled water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). Data analysis was performed using Xcalibur (version 1.6.1). For the analysis of results, the plasma stability of each peptide derivative was expressed as the % remaining at each time point for uncultured samples.

[0191] As a result, it was confirmed that the peptide derivative of the present invention has excellent plasma stability, and in particular, plasma stability is significantly improved even compared to APN5, a conventionally known adiponectin-derived peptide (Table 6).

[0192] Compound number Chemical formula number Plasma stability (% remaining) Human, 30m Human, 120m Rat, 30m Rat, 120m DS-5 1-5 1.4 < 1 >100 94.1 DS-6 1-6 12.6 1.3 >100 >100 DS-8 1-8 39.8 3.3 >100 96 DS-28 1-18 17.6 3.1 >100 >100 DS-35 1-21 2.9 < 1 99.4 89.4 DS-41 1-27 < 1 < 1 >100 99.6 DS-43 adiporon >100 >100 >100 >100 DS-48 1-31 1.1 < 1 >100 84.9 DS-56 1-39 2.8 < 1 70.9 29.4 DS-73 1-50 94.7 75.2 >100 89.3 APN5 P5 < 1 < 1 83.1 70.5 Procaine(reference) 2.8 (5 min) < 1(5 min) 90.3 57.4 Enalapril(reference) >100 97.4 27.9 < 1

[0194] Experimental Example 7. Metabolic Stability Test

[0195] Three types of liver microsomes (Human, Rat, Mouse, 0.5 mg / ml), 0.1 M phosphate buffer (pH 7.4), and the peptide derivative of the present invention were added at a concentration of 1 μM and pre-incubated at 37°C for 5 minutes. Subsequently, NADPH Regeneration System solution was added and incubated at 37°C for 30 minutes. Afterward, to terminate the reaction, an acetonitrile solution containing an internal standard (chlorpropamide) was added, and after centrifugation for 5 minutes (14,000 rpm, 4°C), the supernatant was injected into an LC-MS / MS system to analyze the substrate drug, thereby evaluating metabolic stability. At this time, Verapamil was used as a reference substance for accuracy in general plasma stability tests.

[0196] The amount of substrate remaining from the above reaction was analyzed by LC-MS / MS using an Agilent 1290 infinity series pump system (Agilent, USA) and a Triple Quad 5500 LC-MS / MS system (Applied Biosystems, USA). A Kinetex C18 column (2.1 × 100 mm, 1.7 μm particle size; Phenomenex, USA) was used as the HPLC column, and the mobile phase consisted of distilled water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). TurboSpray Ionization was used as the ion source for the MS / MS, and a Triple Quadruple type mass spectrometer was used. The generated metabolites were quantified using the MRM (multiple reaction monitoring) quantification mode, and data analysis was performed using Analyst software (version 1.6.1).

[0197] As a result, it was confirmed that the peptide derivative of the present invention has excellent metabolic stability, and in particular, its metabolic stability is significantly improved even compared to APN5, a conventionally known adiponectin-derived peptide (Table 7).

[0198] Compound number Chemical formula number Metabolic stability (% remaining) Human, 30m Rat, 30m Mouse, 30m DS-5 1-5 62.5 66.4 95.9 DS-6 1-6 88.0 88.1 96.5 DS-8 1-8 93.9 78.2 83.6 DS-28 1-18 93.8 85.8 96.6 DS-35 1-21 >100 95.8 99.2 DS-41 1-27 95.8 75.1 95.2 DS-43 adiporon 54.9 2.3 3.1 DS-48 1-31 21.6 2.8 20.6 DS-56 1-39 53.9 41.1 10.6 DS-73 1-50 71.6 65.7 78 APN5 P5 1.7 1.3 9.5 Verapamil(reference) 13.4 - -

[0200] Experimental Example 8. CYP Inhibition Analysis

[0201] Human liver microsomes (0.25 mg / ml), 0.1 M phosphate buffer solution (pH 7.4), a cocktail of substrates for five types of drug metabolizing enzymes (Phenacetin 50 μM, S-mephenytoin 100 μM, dextromethorphan 5 μM, midazolam 2.5 μM, diclofenac 10 μM), and the peptide derivative of the present invention were added at concentrations of 0 and 10 μM, respectively, and incubated at 37°C for 5 minutes, after which a NADPH Regeneration System solution was added and incubated at 37°C for 15 minutes. Subsequently, to terminate the reaction, an acetonitrile solution containing an internal standard (chlorpropamide) was added, and after centrifugation for 5 minutes (14,000 rpm, 4°C), the supernatant was injected into an LC-MS / MS system to simultaneously analyze the metabolites of the substrate drug, thereby evaluating the inhibitory activity of the peptide derivative on drug metabolites. At this time, Ketoconazole was used as a reference substance to ensure accuracy in general drug metabolite inhibitory activity evaluations.

[0202] The metabolites of each CYP isoenzyme marker drug generated through the above reaction were analyzed by LC-MS / MS using a Shimadzu Nexera XR system and a TSQ vantage (Thermo). A Kinetex C18 column (2.1 × 100 mm, 2.6 μm particle size; Phenomenex, USA) was used as the HPLC column, and the mobile phase consisted of distilled water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). TurboSpray Ionization was used as the ion source for MS / MS, and a Triple Quadruple type mass spectrometer was used. The generated metabolites were quantified using the MRM (multiple reaction monitoring) quantification mode, and data analysis was performed using Xcalibur (version 1.6.1).

[0203] As a result, the peptide derivative of the present invention inhibits CYP enzymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Table 8), suggesting that it does not cause fatal adverse reactions due to drug interactions.

[0204] Compound number Chemical formula number CYP inhibition (% of control activity) CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 DS-5 1-5 83.2 97.3 80.9 85.5 90.9 DS-6 1-6 86.1 >100 70.2 89.1 94.1 DS-8 1-8 95.1 >100  100 >100 >100 DS-28 1-18 81.7 96.9 87.2 86.1 95.5 DS-35 1-21 77.7 93.6 4.1 97.4 >100 DS-41 1-27 82.7 93.6 75.8 09.6 92.3 DS-43 adiporon 91.6 57.8 66.0 30.3 90.3 DS-48 1-31 79.0 85.0 17.0 78.1 24.1 DS-56 1-39 80.5 100.0 73.5 91.6 9.2 DS-73 1-50 82.7 96.5 85.1 85.9 80.5 APN5 P5 88.8 >100 98.5 92.3 82.9 Ketoconazole (reference) 97.2 >100 >100 >100 26.1

[0206] Experimental Example 9. Evaluation of the efficacy of topical application in hair growth and skin aging improvement in mice

[0207] After shaving the backs of 7-week-old C57BL / 6 mice, the peptide derivative formulations of the present invention were dissolved in bechle (EtOH : polyethylene glycol = 30 : 70, v / v) at a concentration of 0.15 mM each and applied. A solution equivalent to 200 μl per mouse was uniformly applied to the entire back daily for 35 days.

[0208] In addition, skin tissue was excised after the final application to extract mRNA, and the effect on the expression of procollagen, a skin aging factor, was verified using real-time PCR.

[0209] As a result, the proportion of hair growth areas among the areas where hair was initially removed significantly increased in the group treated with the peptide derivative of the present invention. In particular, it was confirmed that the formation of hair follicles was promoted similarly to the group treated with minoxidil, which was used as a positive control (Fig. 18).

[0210] In addition, it was confirmed that procollagen, a skin aging factor, was expressed in the group treated with the peptide derivative of the present invention in amounts similar to or greater than that of APN5, a conventionally known adiponectin-derived peptide (Fig. 19).

[0212] Experimental Example 10. Verification of efficacy in inhibiting triglycerides in adipocytes

[0213] Mouse adipocyte line 3T3-L1 was treated with a differentiation induction agent to differentiate into adipocytes filled with triglycerides, and then the peptide derivatives of the present invention were treated at a series of concentrations (10, 30 μM), cultured for 24 hours, and the cells were obtained to measure the triglyceride content. As a result, it was confirmed that treatment with the peptide derivatives of the present invention reduced the triglyceride content in a concentration-dependent manner (Fig. 20a).

[0214] Meanwhile, mouse adipocyte line 3T3-L1 was differentiated into adipocytes by treating them with a differentiation induction reagent at a concentration of 10 μM of the peptide derivative of the present invention before differentiation induction, and the cells were obtained and the triglyceride content was measured. As a result, it was confirmed that treatment with the peptide derivative of the present invention inhibits triglyceride accumulation (Fig. 20b).

[0216] Experimental Example 11. Verification of efficacy in improving muscle cell-sensitive skin

[0217] After culturing the human muscle cell line RD cell line, when the cell count reached 90%, the medium was replaced with serum-free medium and treated with 50 mM of lactic acid (LA), a substance that induces skin sensitivity, and 10 μM of the peptide derivative of the present invention. After 4 hours, the cells were harvested and mRNA was extracted to observe the effect on the expression of CGRP, a pain mediator neurotransmitter.

[0218] As a result, it was confirmed that when treated with the peptide derivative of the present invention, the expression of pain mediators was significantly reduced compared to when treated with lactic acid, and was at a level similar to or lower than when nothing was treated (Fig. 21). In other words, it can be seen that the peptide derivative of the present invention can significantly suppress the expression of genes related to skin sensitivity induced by lactic acid.

[0220] Although the embodiments have been described above with reference to the limited drawings, those skilled in the art can apply various technical modifications and variations based on the above. For example, suitable results may be achieved even if the described techniques are performed in a different order than described, and / or if the components of the described system, structure, device, circuit, etc. are combined or assembled in a form different from described, or replaced or substituted by other components or equivalents.

[0221] Therefore, other implementations, other embodiments, and equivalents to the claims also fall within the scope of the claims set forth below.

Claims

Claim 1 A peptide derivative characterized by being any one selected from the group consisting of peptide derivatives represented below: [Chemical Formula 1-5] ;[Chemical Formula 1-6] ;[Chemical Formula 1-8] ;[Chemical Formula 1-18] ; and [Chemical Formula 1-31] . Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 A cosmetic composition for improving skin aging comprising the peptide derivative of claim 1 as an active ingredient. Claim 7 A cosmetic composition for promoting hair growth comprising the peptide derivative of claim 1 as an active ingredient. Claim 8 Pharmaceutical composition for the prevention or treatment of hair loss and sensitive skin comprising a peptide derivative selected from the group consisting of the following as an active ingredient: [Chemical Formula 1-8] ;[Chemical Formula 1-18] ; and [Chemical Formula 1-31] . Claim 9 delete Claim 10 delete Claim 11 delete

Citation Information

Patent Citations

  • Composition for promoting hair growth comprising peptide derived from adiponectin

    KR1020180100945A